UBS Oconnor LLC cut its holdings in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 25.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,319 shares of the company’s stock after selling 7,681 shares during the period. UBS Oconnor LLC’s holdings in Crispr Therapeutics were worth $638,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. boosted its holdings in Crispr Therapeutics by 96.7% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,627 shares of the company’s stock worth $46,000 after acquiring an additional 800 shares in the last quarter. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Crispr Therapeutics by 37.5% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 4,400 shares of the company’s stock valued at $126,000 after purchasing an additional 1,200 shares in the last quarter. Resources Investment Advisors Inc. bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at $43,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Crispr Therapeutics by 79.4% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,987 shares of the company’s stock valued at $112,000 after purchasing an additional 1,765 shares in the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Crispr Therapeutics by 24.4% during the fourth quarter. LPL Financial LLC now owns 9,809 shares of the company’s stock valued at $280,000 after purchasing an additional 1,924 shares in the last quarter. 42.24% of the stock is currently owned by hedge funds and other institutional investors.
In related news, President Rodger Novak sold 8,693 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $40.01, for a total transaction of $347,806.93. Following the completion of the sale, the president now owns 1,024,534 shares in the company, valued at $40,991,605.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 108,693 shares of company stock valued at $4,381,895 in the last quarter. 37.70% of the stock is currently owned by company insiders.
Shares of NASDAQ:CRSP traded down $0.76 during trading on Monday, hitting $37.15. 317,037 shares of the company’s stock were exchanged, compared to its average volume of 750,954. Crispr Therapeutics AG has a 52-week low of $22.22 and a 52-week high of $73.90. The stock has a market capitalization of $1.99 billion, a P/E ratio of -10.80 and a beta of 3.11.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). Crispr Therapeutics had a negative return on equity of 48.35% and a negative net margin of 5,281.08%. The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $1.56 million. The company’s quarterly revenue was down 99.7% compared to the same quarter last year. Research analysts predict that Crispr Therapeutics AG will post -3.43 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “UBS Oconnor LLC Trims Holdings in Crispr Therapeutics AG (NASDAQ:CRSP)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/15/crispr-therapeutics-ag-crsp-shares-sold-by-ubs-oconnor-llc.html.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
See Also: What are gap-up stocks?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.